Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305
Todd T. Brown(Johns Hopkins University), Timothy Wilkin(Cornell University), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), Craig W. Hendrix(Unknown), Roy M. Gulick(New York University), Kenneth H. Mayer(Miriam Hospital), Krista Yuhas(Fred Hutch Cancer Center), Wairimu Chege(National Institutes of Health), Karen L. Klingman(National Institutes of Health), Mark A. Marzinke(Family Health International 360), Ying Qing Chen(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 5
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k